Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies

Monica M. Mita,E. K. Rowinsky,M. Goldston,Alain C. Mita,Quincy Chu,Samira Syed,H. L. Knowles,Victor M. Rivera,Camille L. Bedrosian,Anthony W. Tolcher

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies

2004

Monica M. Mita
E. K. Rowinsky
M. Goldston
Alain C. Mita
Quincy Chu
Samira Syed
H. L. Knowles
Victor M. Rivera
Camille L. Bedrosian
Anthony W. Tolcher

3076 Background: AP23573, a non-prodrug rapamycin analog, potently inhibits mTOR, a downstream effector of the PI3K/Akt and nutrient signaling pathways. AP23573 demonstrated potent inhibition of pr...

Keywords:

Discovery and development of mTOR inhibitors
Pharmacodynamics
Pharmacology
Medicine
Pharmacokinetics
Signal transduction
Effector
Protein kinase B
PI3K/AKT/mTOR pathway
Refractory
every other week

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations